What IGBMC does

IGBMC (Institut de génétique et de biologie moléculaire et cellulaire) is a French public biomedical research institute operating as a Unité Mixte de Recherche jointly under CNRS (UMR 7104), Inserm (U 1258) and the Université de Strasbourg. Headquartered on a 40,000 m² campus in Illkirch-Graffenstaden near Strasbourg, it is organised around five departments (Biology of Development and Stem Cells; Integrative Structural Biology; Functional Genomics and Cancer; Translational Medicine and Neurogenetics; and Direction générale) that house 50 research teams and a total of 740 collaborators, including 53 post-doctoral researchers, 227 doctoral/master students and 220 technicians/engineers.

The institute's core offering is a federation of nine complementary technological platforms and infrastructures: the Integrated Structural Biology platform (combining biocrystallography, electron microscopy, super-resolution microscopy and molecular biophysics), the CytoEast cytometry platform, the ScreenTech/INGESTEM high-throughput phenotypic screening platform, the GenomEast genomics platform, the PluriCell East pluripotent stem cell platform, the Imaging Center of IGBMC (ICI), the Proteomics platform, the Institut clinique de la souris (ICS) for preclinical mouse studies, and the Centre de biologie intégrative (CBI). These are complemented by shared scientific services (zebrafish and rodent facilities, baculovirus expression, molecular biology and virus tools, mediaprep) and the EUR IMCBio graduate training program. Over the past decade, IGBMC teams have contributed approximately 40 new disease gene discoveries, 500+ scientific publications (from the Translational Medicine and Neurogenetics department alone), 15+ patents/licenses, and the creation of two biotech startups (AAVLife/Annapurna Therapeutics and Dynacure).

Commercially, IGBMC is a non-profit public institute and does not disclose revenue or pricing. Its revenue mechanics are dominated by recurring institutional funding from CNRS, Inserm and the Université de Strasbourg, augmented by competitive grants from ERC, ANR, Fondation ARC, FRM, La Ligue, Bettencourt, France Génomique, INCa and the EU, supplemented by donations, platform-access and collaboration services for external academic and industry partners, and technology-transfer/licensing income from its patent portfolio. The institute is led by Director Patrick Schultz and serves academic researchers, pharmaceutical and biotech industry partners (including Lysogene), clinicians and patient associations (via the Genida participatory database), and trainees.

Name

IGBMC

Legal name

Institut de génétique et de biologie moléculaire et cellulaire (IGBMC) - CNRS UMR 7104 - Inserm U 1258

Website

https://igbmc.fr

Company type

Private

Operating status

Operating

Headcount range

501–1,000 employees

Short description

IGBMC is a French public biomedical research institute (CNRS UMR 7104 / Inserm U 1258 / Université de Strasbourg) in Illkirch-Graffenstaden, employing 740 collaborators across 50 teams and nine integrated scientific platforms covering structural biology, genomics, imaging, proteomics, cytometry, stem cells and preclinical models to advance genetics and disease research.

Ownership category

akta.pro rank

Headquarters

HQ city

Illkirch-graffenstaden

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Others

Revenue model

1. Public institutional funding (CNRS / Inserm / Université de Strasbourg): Core funding as a Unité Mixte de Recherche (UMR CNRS 7104 - Inserm U 1258) jointly hosted with the Université de Strasbourg.
2. Competitive grant funding: Funding from national and European agencies including ERC, ANR, Fondation ARC, Fondation pour la Recherche Médicale, La Ligue, France Génomique, Bettencourt Foundation, and the European Union, as evidenced by partner logos displayed on the institute website.
3. Technology transfer and licensing: Patents, licenses and creation of startups (e.g., AAVLife / Annapurna Therapeutics; Dynacure) from translational research, especially in the Medicine Translationnelle et Neurogénétique department.
4. Donations: Accepts donations from individuals and supporters ('Faites un don' / 'Make a donation' pathway on the institute website).
5. Platform access and collaboration services: External academic and industry partners can access the institute's technological platforms and scientific services (e.g., proteomics, imaging, CytoEast, GenomEast, ICS, structural biology) under defined collaboration modes.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

IGBMC is a French public biomedical research institute (CNRS UMR 7104 / Inserm U 1258, co-hosted with the Université de Strasbourg) that conducts fundamental and translational research in genetics, molecular and cellular biology across cancer, rare diseases and regenerative medicine. It sells access to a federation of named scientific platforms (Integrated Structural Biology, CytoEast, GenomEast, PluriCell East, ICI imaging, ScreenTech/IngEstem, Proteomics) and shared services (ICS preclinical mouse facility, animaleries, baculovirus, molecular biology/virus, mediaprep), and offers graduate research training through the EUR IMCBio program. Its 'product' is collaborative research and platform-access services delivered to academic and industry partners rather than off-the-shelf commercial products.

Product overview

IGBMC is a public French research institute (CNRS UMR 7104 / Inserm U 1258 / Université de Strasbourg) and not a software vendor; its 'product' portfolio is a federation of scientific platforms and services that researchers can access through collaboration. The offering combines two research infrastructures (Centre de biologie intégrative and Institut clinique de la souris) with seven named platforms — Biologie Structurale Intégrée, CytoEast, ScreenTech/IngEstem, GenomEast, PluriCell East, the Imaging Center of IGBMC (ICI), and Protéomique — alongside shared scientific services (Animalerie aquatique, Animalerie rongeurs, Baculovirus, Biologie moléculaire et virus, Médiaprep), an internal department structure (Direction générale, Biologie du développement et cellules souches, Biologie structurale intégrative, Génomique fonctionnelle et cancer, Médecine translationnelle et neurogénétique), and a graduate training program (EUR IMCBio). Together, these constitute IGBMC's collaborative research offering rather than a unified commercial product.

Differentiator

Problem solved

Functional benefit

Brands

• Centre de biologie intégrative: Centre for integrative biology infrastructure within IGBMC
• Institut clinique de la souris (ICS)
• Biologie Structurale Intégrée
• CytoEast
• GenomEast
• PluriCell East
• Imaging Center of IGBMC (ICI)
• EUR IMCBio
• Genida

Products and services

• Centre de biologie intégrative (Centre for Integrative Biology) One of IGBMC's two research infrastructure units, hosting large-scale integrative biology activities and interdisciplinary research infrastructure at the Illkirch campus; access via the institute's infrastructure pages.
• Institut clinique de la souris (ICS / Mouse Clinical Institute) IGBMC's clinical and phenotyping infrastructure for the mouse, supporting in vivo pharmacology, phenotyping, translational studies and disease-model characterization for internal teams and external collaborators.
• Biologie Structurale Intégrée (Integrated Structural Biology Platform) Structural biology platform offering biocrystallography, electron microscopy, super-resolution microscopy, sample preparation and molecular biophysics services to internal teams and external collaborators.
• CytoEast Flow cytometry platform providing cell sorting and analytical cytometry services, with dedicated sorter and analyzer equipment streams for cellular analysis.
• Analyse phénotypique et criblage cellulaire (ScreenTech / IngEstem) High-throughput phenotypic analysis and cell screening platform supporting automated and quantitative cell-based assays for drug discovery and functional studies.
• GenomEast Genomics platform providing sequencing and genome-scale analyses for IGBMC teams and external partners; a node in the national France Génomique infrastructure for genomics services.
• PluriCell East Pluripotent cell / stem cell platform supporting derivation, culture and differentiation of pluripotent cell lines including iPSC for internal and external users.
• Imaging Center of IGBMC (ICI) Photon microscopy / imaging center providing advanced light microscopy resources to research teams across the institute.
• Protéomique (Proteomics) Proteomics platform offering peptide synthesis and mass spectrometry services for protein identification and characterization for internal teams and external collaborators.
• Animalerie aquatique (Zebrafish aquatic facility) Aquatic animal facility dedicated to zebrafish husbandry and experimentation for internal and external research projects.
• Animalerie rongeurs (Rodents house) Rodent animal facility providing breeding, housing and experimental support with mice and rats for IGBMC research teams and partners.
• Baculovirus Service producing and providing baculovirus-based expression tools for recombinant protein production in insect cells.
• Biologie moléculaire et virus (Molecular biology and virus) Molecular biology service producing viral tools and related reagents for research projects at the institute.
• Médiaprep Service preparing media and buffers for cell culture and laboratory use at IGBMC.
• EUR IMCBio graduate program Graduate school training program in Integrative Molecular and Cellular Biology, hosted by IGBMC in partnership with the Université de Strasbourg, supporting PhD and master's training.

Quantifiable outcome

• Discovery of ~40 new genes involved in human diseases over the past decade
• +3 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Seven partnerships are on record, tiered flagship / core hosting institution, strategic infrastructure partner, regional institutional partner and strategic therapeutic development partner.

• CNRS (Centre national de la recherche scientifique)flagship / core hosting institutionStrategic or Co-development PartnerIGBMC is jointly operated as a Unité Mixte de Recherche under CNRS (UMR 7104). CNRS is one of the three tutelles (host institutions) that govern and fund the institute alongside Inserm and the Université de Strasbourg. The CNRS logo appears in the institute's footer and on all official materials.
• Inserm (Institut national de la santé et de la recherche médicale)flagship / core hosting institutionStrategic or Co-development PartnerIGBMC is jointly operated as a Unité Mixte de Recherche under Inserm (U 1258). Inserm is one of the three tutelles that govern and fund the institute. The Inserm logo is featured in the institute's footer.
• Université de Strasbourg (UDS)flagship / core hosting institutionStrategic or Co-development PartnerIGBMC is jointly hosted with the Université de Strasbourg as one of its three tutelles. The university hosts the newsletter signup system used by IGBMC and co-supervises training programs such as EUR IMCBio.
• France Génomiquestrategic infrastructure partnerStrategic or Co-development PartnerFrance Génomique logo featured among IGBMC partners; the GenomEast platform at IGBMC is a node contributing to the national France Génomique infrastructure for genomics services.
• Strasbourg.eu (Eurométropole de Strasbourg)regional institutional partnerStrategic or Co-development PartnerStrasbourg.eu (Eurométropole) logo featured as a partner on the IGBMC homepage, indicating metropolitan support and ecosystem collaboration.
• Département du Bas-Rhinregional institutional partnerStrategic or Co-development PartnerBas-Rhin departmental logo featured as a partner on the IGBMC homepage, indicating departmental support.
• Lysogenestrategic therapeutic development partnerStrategic or Co-development PartnerIGBMC's Fragile-X syndrome subgroup collaborates with Lysogene to test DGKK as a therapeutic target for the Fragile-X syndrome, building on AAV-based delivery work.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Francis Crick Institute: Large UK biomedical research institute with similar multi-disciplinary team structure, technology platform federation, and translational orientation, serving a comparable academic-and-industry partner mix.
• Institut Curie: French public research-hospital hybrid combining fundamental biology, translational cancer research, and clinical care, with technology platforms and industry partnerships closely paralleling IGBMC's translational model.
• Max Planck Institute for Molecular Genetics: German basic-research institute focused on molecular genetics, genomics, and disease mechanisms; comparable research scope, large team-based structure, and publicly funded operating model.
• Whitehead Institute for Biomedical Research: MIT-affiliated biomedical research institute with similar team-based structure, focus on genetics/molecular biology/cancer, and a comparable record of training future biotech founders.
• Institut Pasteur: Major French public biomedical research institute with comparable scale, multi-department research structure, and a similar model of combining fundamental research with technology platforms and industry partnerships. Operates in the same French public-research ecosystem under the same tutelles.
• Centre for Genomic Regulation (CRG): Barcelona-based biomedical research institute with comparable scale, multi-disciplinary team structure covering genomics, bioinformatics, and cell biology, and similar public-funder governance model.
• Broad Institute of MIT and Harvard: US biomedical and genomic research institute with a comparable mix of large-scale platforms (genomics, proteomics, chemical biology), translational pipelines, and significant startup/spin-out creation from fundamental research.
• Helmholtz Zentrum München – German Research Center for Environmental Health: Large German public research center with integrated platforms for genomics, proteomics, imaging, and disease modeling, plus an active technology-transfer and industry-partnership model analogous to IGBMC's.
• European Molecular Biology Laboratory (EMBL): Intergovernmental European molecular biology research organization with integrated structural biology, genomics, and cell biology platforms — directly comparable to IGBMC's platform stack and translational mission.
• Wellcome Sanger Institute: UK genomics and genetics research institute with comparable scale of operations, large-scale sequencing platform (comparable to GenomEast), and similar disease-gene discovery track record.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/igbmc
• Xx.com/IGBMC
• Facebookfacebook.com/IGBMCinstitut

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IGBMC